Breast Cancer

Triple negative breast cancer (TNBC)

Locally advanced/ metastatic TNBC

Bone metastatic breast cancer (TNBC or ER+ and/or PR+)

Advanced metastatic or recurrent tumors with pathogenic BRCA 1/2 mutated

TNBC or HR+

BRCA Mutant

10302: Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

10546: Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

10551: Phase Ib/II Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors

10146 Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer

10149: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer

10525: A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: December 11, 2023